Stocktoria
Profound Medical Corp. PROF
Profound Medical Corp. (PROF) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $16.1M at a -264.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.904 |
| Retained earnings / assets | -3.714 |
| EBIT / assets | -0.532 |
| Equity / liabilities | 6.017 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PROF | Profound Medical Corp. | 5/9 | -3.44 | — | +50.7% |
| VVOS | Vivos Therapeutics, Inc. | 2/9 | — | — | +16% |
| NEPH | NEPHROS INC | 6/9 | — | 32.8 | +32.7% |
| SNOA | Sonoma Pharmaceuticals, Inc. | 2/9 | — | — | +36.7% |
| MDAI | Spectral AI, Inc. | 3/9 | -11.78 | — | -33.6% |
| NXGL | NEXGEL, INC. | 5/9 | -6.91 | — | — |
| WOK | WORK Medical Technology Group LTD | 4/9 | — | — | -14.4% |
About Profound Medical Corp.
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. It operates in Canada, Germany, the United States, China, and Finland. Profound Medical Corp. is headquartered in Mississauga, Canada.
FAQ
Is PROF financially healthy?
Profound Medical Corp.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does PROF pay a dividend?
No, Profound Medical Corp. does not currently pay a dividend.
How profitable is PROF?
In FY2025, Profound Medical Corp. had a net margin of -264.4% and a return on equity of -64.1%.
What is the analyst price target for PROF?
The average Wall-Street price target for Profound Medical Corp. is $11.14, about 60.8% above the recent price, from 5 analysts.
Is PROF a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Profound Medical Corp.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.